Joseph R. Berger, MD, looks forward to expanded discussions on the best treatment approaches for neuromyelitis optica spectrum disorders at the upcoming ECTRIMS 2024 meeting, including head-to-head comparisons of newer therapies and their real-world effectiveness. Dr Berger is also interested in advancements in biomarker research to better monitor disease activity and treatment response.
Further insights into antibody-negative cases and their underlying causes, as well as the connection between these disorders and co-existing conditions like lupus, would be valuable for improving our understanding and management of these diseases, Dr Berger suggests. He concludes by offering that current research on these topics could significantly enhance our approach to treating and studying these complex conditions.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: ECTRIMS 2024: Anticipating New Treatment Strategies and Biomarkers in NMOSD - Medscape - Sep 09, 2024.
Comments